Tenapanor (大腸躁鬱症的治療藥) - 2023年為止的預測與市場分析
Tenapanor (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 55 Pages
|Tenapanor (大腸躁鬱症的治療藥) - 2023年為止的預測與市場分析 Tenapanor (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023|
|出版日期: 2014年12月31日||內容資訊: 英文 55 Pages||
本報告提供大腸躁鬱症 (IBS) 治療藥物──Tenapanor之相關調查，提供您疾病概要與免疫學，疾病管理，競爭情形，未滿足需求機會，開發平台評估，主要企業的資訊，今後的市場預測等資訊。
Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.
Tenapanor is being developed for the treatment of IBS-C. It was initially developed by Ardelyx, but in October 2012, the company entered into a partnership with AstraZeneca, which gained the exclusive worldwide licensing rights to tenapanor (Ardelyx, press release, October 8, 2012).